Edge Therapeutics, Inc. (NASDAQ:EDGE) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
The 2017 Annual Meeting of Stockholders (the Annual Meeting) of
Edge Therapeutics, Inc. (Edge) was held on June 20, 2017. A
quorum was present at the Annual Meeting. Matters submitted to
the stockholders and voted upon at the meeting, which are more
fully described in Edges Proxy Statement filed with the
Securities and Exchange Commission on April 28, 2017, were (1)
the election of Isaac Blech, James Loughlin, and R. Loch
Macdonald, .M.D., Ph.D. as Class B directors to Edges board of
directors to hold office until the 2020 Annual Meeting of
Stockholders and (2) the ratification of the selection of KPMG
LLP as Edges independent registered public accounting firm for
the fiscal year ending December 31, 2017. At the Annual Meeting,
Edges stockholders approved the two proposals, and the final
results were as follows:
(1) |
Election of Isaac Blech, James Loughlin, and R. Loch
Macdonald, M.D., Ph.D. as a Class B directors, to hold officer until the 2020 Annual Meeting of Stockholders: |
Nominees |
For |
Withheld |
Broker Non-Votes |
|||
|
Isaac Blech |
18,458,975 |
3,617,268 |
6,311,098 |
|||
|
James Loughlin |
19,606,653 |
2,469,590 |
6,311,098 |
|||
|
R. Loch Macdonald, M.D., Ph.D. |
19,431,836 |
2,644,407 |
6,311,098 |
(2) |
Ratification of the selection of KPMG LLP as Edges
independent registered public accounting firm for the year ending December 31, 2017: |
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
28,192,940 |
193,071 |
1,330 |
About Edge Therapeutics, Inc. (NASDAQ:EDGE)
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize, hospital-based therapies capable of transforming treatment paradigms in the management of life-threatening neurological and other conditions. Edge is evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). This study will evaluate EG-1962’s ability to improve patient outcomes versus standard of care oral nimodipine after an aSAH resulting from a ruptured brain aneurysm. Edge’s product candidates utilize Precisa, a platform with a approach that seeks to enable targeted and sustained drug exposure at the site of injury, while potentially avoiding off-target side effects associated with systemic delivery. Edge is also using its Precisa development platform to develop additional product candidates targeting other acute, serious conditions where limited or no current therapies exist.
